Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Listen to this summary
SYNCHRONIZE-CVOT asked whether the dual glucagon/GLP-1 receptor agonist survodutide is cardiovascularly safe in adults with obesity and either established cardiovascular disease, chronic kidney disease, or elevated cardiovascular risk. In this randomised, placebo-controlled trial of 5,530 participants followed for a median of 22 months, the primary composite endpoint occurred in 3.7% of survodutide-treated participants versus 4.1% on placebo (HR 0.89, 95% CI 0.67–1.18), meeting the prespecified non-inferiority criterion. Gastrointestinal adverse events, particularly nausea and vomiting, were substantially more common with survodutide, though serious adverse event rates were similar across groups.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Lancet (London, England)
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
Nov 12, 2026 · Lancet (London, England)
Lynch syndrome.
Nov 12, 2026 · Lancet (London, England)
Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial.
More in Nuclear Medicine
View all →Nov 20, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Myocardial Extraction Fraction and Circulation-Dependent Changes of 99mTc-4BOH: Implications for Quantitative SPECT Myocardial Perfusion Imaging.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 16, 2026 · The New England journal of medicine
Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.
Nov 13, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Relationship between integrated myocardial flow reserve and obstructive coronary artery disease and major adverse cardiac events: Findings from the multicenter REFINE PET Registry.
Nov 11, 2026 · The New England journal of medicine
Preventing Malaria Infections and Moving toward Malaria Elimination.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


